In August 2018, the first PCSK9 inhibitor was approved in China for the treatment of HoFH in adults or adolescents over 12 years of age (World Health Organization, 2018a), thus enabling the development of new approaches to the treatment of patients with FH in China. The gene discussed is PCSK9; the disease is homozygous familial hypercholesterolemia.